Literature DB >> 24307921

Topical corticosteroid application and the structural and functional integrity of the epidermal barrier.

James Q Del Rosso1, Kimberly Cash.   

Abstract

Topical corticosteroids are a very important part of the treatment of many skin disorders, especially eczematous dermatoses. When utilized properly and judiciously these agents often achieve excellent results in clearing or markedly improving many dermatological disorders. As some studies have shown, topical corticosteroids, despite their ability to decrease inflammation through several mechanisms, induce abnormalities in lipid synthesis and intercellular bilayer structure in the stratum corneum, which appear to prolong epidermal barrier recovery. These adverse effects may contribute to eariier eczematous flaring if measures to provide barrier repair are not undertaken. In addition, although topical corticosteroids are applied only to sites affected by the skin eruption, the incorporation of "barrier friendly" excipients into the vehicle that improve stratum corneum permeability barrier function and integrity is very rational.

Entities:  

Year:  2013        PMID: 24307921      PMCID: PMC3848648     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  44 in total

1.  The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype.

Authors:  Parviz Ahmad-Nejad; Salima Mrabet-Dahbi; Kristine Breuer; Martina Klotz; Thomas Werfel; Udo Herz; Klaus Heeg; Michael Neumaier; Harald Renz
Journal:  J Allergy Clin Immunol       Date:  2004-03       Impact factor: 10.793

2.  The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin.

Authors:  James Q Del Rosso; Jacqueline Levin
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

Review 3.  Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials.

Authors:  J Schmitt; L von Kobyletzki; A Svensson; C Apfelbacher
Journal:  Br J Dermatol       Date:  2010-11-23       Impact factor: 9.302

4.  Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids.

Authors:  Jens-Michael Jensen; Kerstin Ahrens; Josef Meingassner; Andreas Scherer; Matthias Bräutigam; Anton Stütz; Thomas Schwarz; Regina Fölster-Holst; Jürgen Harder; Regine Gläser; Ehrhardt Proksch
Journal:  Exp Dermatol       Date:  2011-06-24       Impact factor: 3.960

5.  Effect of moisturizers on epidermal barrier function.

Authors:  Marie Lodén
Journal:  Clin Dermatol       Date:  2012 May-Jun       Impact factor: 3.541

6.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis.

Authors:  Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

7.  Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities.

Authors:  Jack S Kao; Joachim W Fluhr; Mao-Qiang Man; Ashley J Fowler; Jean-Pierre Hachem; Debra Crumrine; Sung K Ahn; Barbara E Brown; Peter M Elias; Kenneth R Feingold
Journal:  J Invest Dermatol       Date:  2003-03       Impact factor: 8.551

8.  Abnormality of water barrier function in psoriasis. Role of ceramide fractions.

Authors:  S Motta; M Monti; S Sesana; L Mellesi; R Ghidoni; R Caputo
Journal:  Arch Dermatol       Date:  1994-04

9.  The effect of ceramide-containing skin care products on eczema resolution duration.

Authors:  Zoe Diana Draelos
Journal:  Cutis       Date:  2008-01

10.  Barrier-restoring therapies in atopic dermatitis: current approaches and future perspectives.

Authors:  Y Valdman-Grinshpoun; D Ben-Amitai; A Zvulunov
Journal:  Dermatol Res Pract       Date:  2012-08-22
View more
  6 in total

Review 1.  Understanding the Epidermal Barrier in Healthy and Compromised Skin: Clinically Relevant Information for the Dermatology Practitioner: Proceedings of an Expert Panel Roundtable Meeting.

Authors:  James Del Rosso; Joshua Zeichner; Andrew Alexis; David Cohen; Diane Berson
Journal:  J Clin Aesthet Dermatol       Date:  2016-04-01

Review 2.  Efinaconazole in Onychomycosis.

Authors:  Aditya K Gupta; Mesbah Talukder
Journal:  Am J Clin Dermatol       Date:  2021-12-13       Impact factor: 7.403

3.  Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).

Authors:  Madhu Rengasamy; Manjunath M Shenoy; Sunil Dogra; Neelakandhan Asokan; Ananta Khurana; Shital Poojary; Jyothi Jayaraman; Ameet R Valia; Kabir Sardana; Seetharam Kolalapudi; Yogesh Marfatia; P Narasimha Rao; Ramesh M Bhat; Mahendra Kura; Deepika Pandhi; Shyamanta Barua; Vibhor Kaushal
Journal:  Indian Dermatol Online J       Date:  2020-07-13

4.  Impetiginized Dyshidrotic Eczema.

Authors:  Georgi Tchernev; Matteo Zanardelli; Cristiana Voicu; Ilko Bakardzhiev; Torello Lotti; Jacopo Lotti; Katlein França; Atanas Batashki; Uwe Wollina
Journal:  Open Access Maced J Med Sci       Date:  2017-07-19

5.  Seungmagalgeun-Tang, a Traditional Herbal Formula, Alleviates Skin Inflammation and Depression-Like Behavior in Atopic Dermatitis Mice under Sleep Deprivation Conditions.

Authors:  Ly Thi Huong Nguyen; Min-Jin Choi; Heung-Mook Shin; In-Jun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-23       Impact factor: 2.629

Review 6.  Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits.

Authors:  Mark G Lebwohl; Emil A Tanghetti; Linda Stein Gold; James Q Del Rosso; Nelly K Gilyadov; Abby Jacobson
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.